JTCS Tips for Better Browsing
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Daenen, W.
Right arrow Articles by Lesaffre, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Daenen, W.
Right arrow Articles by Lesaffre, E.

The Journal of Thoracic and Cardiovascular Surgery, Vol 106, 918-927, Copyright © 1993 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association


ARTICLES

The Bjork-Shiley Monostrut valve. Clinical experience in 647 patients

W Daenen, C Van Kerrebroeck, G Stalpaert, B Mertens and E Lesaffre
Department of Cardiac Surgery, University Hospital Gasthuisberg, Leuven, Belgium.

A total of 647 consecutive patients underwent valve replacement with a Bjork-Shiley Monostrut valve (Shiley, Inc., Irvine, Calif.) from January 1, 1984, through December 31, 1988. A total of 135 patients (20.8%) had had a previous cardiac correction. Overall hospital mortality was 6.8%. Preoperative functional class, cardiopulmonary bypass time, aortic crossclamping time, and cause of valve replacement influenced in-hospital mortality significantly (univariate analysis). The median follow-up was 30 months. Overall actuarial survival was 81% +/- 4% at 6 years. Univariate and multivariate regression analysis showed that preoperative functional class, total cardiopulmonary bypass time, size of mitral prosthesis, and pure mitral insufficiency significantly influenced total mortality after valve replacement. Additional coronary bypass grafting and redo valve replacement did not. The actuarial rate of freedom from thromboembolism was 86% +/- 4% at 6 years. There were no cases of valve thrombosis. Patients having a thromboembolic event showed a higher probability of late death after native valve replacement.


This article has been cited by other articles:


Home page
Eur. J. Cardiothorac. Surg.Home page
W.R. E. Jamieson, R. T. Miyagishima, G. L. Grunkemeier, E. Germann, C. Henderson, G. J. Fradet, L. H. Burr, and S. V. Lichtenstein
Bileaflet mechanical prostheses performance in mitral position
Eur. J. Cardiothorac. Surg., June 1, 1999; 15(6): 786 - 794.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
C. E.E. Kuntze, E. H. Blackstone, and T. Ebels
Thromboembolism and mechanical heart valves: a randomized study revisited
Ann. Thorac. Surg., July 1, 1998; 66(1): 101 - 107.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1993 by The American Association for Thoracic Surgery.